CN108727460A - Betulonic acid derivative and its synthetic method and application - Google Patents
Betulonic acid derivative and its synthetic method and application Download PDFInfo
- Publication number
- CN108727460A CN108727460A CN201810700317.4A CN201810700317A CN108727460A CN 108727460 A CN108727460 A CN 108727460A CN 201810700317 A CN201810700317 A CN 201810700317A CN 108727460 A CN108727460 A CN 108727460A
- Authority
- CN
- China
- Prior art keywords
- compound
- added
- reaction
- synthesis
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@@](CO)(C*1)*[C@]1N(C=CC(*)=N1)C1=O Chemical compound C[C@@](CO)(C*1)*[C@]1N(C=CC(*)=N1)C1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of formulas（Ⅰ）Shown in betulic acid derivative and its synthetic method and application, which contains there are one betulic acid part, with attachment（linker）1,2,3- triazole covalent bond at the C-2 of betulic acid part, attachment and the fluoro- arabinoside nucleoside part of covalent bond 2 '-.Compound provided by the invention is chemically to be designed to deal with the water-soluble low problem of betulic acid, and betulic acid and nucleoside compound are linked together by stable 1,2,3- triazole attachment.
Description
Technical field
The invention belongs to medicine and its prepare and applied technical field, and in particular to a kind of Betulonic acid derivative and its
Synthetic method and application.
Background technology
Betulic acid (Betulinic acid, BA) is a kind of pentacyclic triterpenoid, and it is withered to be present in silver birch, summer
In the various plants such as grass, pawpaw.The study found that betulic acid has extensive physiological activity, there is AntiHIV1 RT activity, antitumor, anti-inflammatory
Etc. effectiveness.Compared to betulic acid, derivative has preferably activity, such as RPR103611 in AntiHIV1 RT activity, antitumor etc.
The clinical trial of AntiHIV1 RT activity is in PA457 (bevirimat), NVX-207 is carrying out antitumor clinical trial.
But since its dissolubility in water is too poor, cause bioavilability low and it is internal transmission, metabolism etc. the shortcomings that.
Invention content
The main purpose of the present invention is to provide a kind of Betulonic acid derivative, another object is to provide such chemical combination
The synthetic method of object, a further object are to provide application of such compound in preparing antitumor and antiviral drugs.
The purpose of the present invention is what is realized in the following manner：
A kind of Betulonic acid derivative or its pharmaceutically acceptable salt, hydrate or prodrug, structural formula such as formula (I) institute
Show：
Wherein：X=NH or O, Y=OH or NH2, R1It is H, C1-C20Substitution or unsubstituted group.
Structural formula Betulonic acid derivative as shown in formula (I) is specially structural formula such as formula i, ii, iii, iv, v, vi institutes
The compound shown：
Such as the synthetic method of above-mentioned Betulonic acid derivative, synthesis path are as follows：
Wherein：Y=OH or NH2, R1It is C1-C20Substitution or unsubstituted group；
Specific synthesis step is as follows：
The synthesis of compound 2：Compound 1 is dissolved in acetone or tetrahydrofuran, 0 DEG C of addition Jones reagent, after completion of the reaction
Methanol and water quenching is added to go out reaction, solvent evaporated extracts and uses column chromatography to obtain compound as white solid 2；
The synthesis of compound 3：Compound 2 is dissolved in dichloromethane, 0 DEG C is added 1- (3- dimethylamino-propyls) -3- ethyls carbon two
Inferior amine salt hydrochlorate (EDC), 4-dimethylaminopyridine (DMAP) stir 30min, add corresponding amine, are stirred at room temperature and reacted
Night, extraction are evaporated column chromatography for separation and obtain compound 3；
The synthesis of compound 4：Compound 3 is dissolved in tetrahydrofuran, and KN (SiMe are added3)2Tetrahydrofuran solution and Et3B's
Tetrahydrofuran solution；Propargyl bromide is added after being stirred to react 1h.Hydrochloric acid neutralization reaction after completion of the reaction, organic extractant phase are evaporated rear pillar
Chromatographic isolation obtains compound 4；
The synthesis of compound 5：Compound 4 is dissolved in the mixed solvent of the tert-butyl alcohol and water, and n,N-diisopropylethylamine and corresponding is added
Nucleosides, stirring 30 minutes after be added CuI acetonitrile solution the reaction was continued overnight.Solvent evaporated after completion of the reaction, pillar layer separation
Obtain compound 5.
The synthesis of compound 6：Compound 2 is dissolved in dichloromethane, and 0 DEG C of dropwise addition oxalyl chloride, solvent evaporated, is re-dissolved in after completion of the reaction
CH2Cl2, corresponding alcohol stirring is added, is evaporated to obtain compound 6；
The synthesis of compound 7：Compound 6 is dissolved in tetrahydrofuran, and KN (SiMe are added3)2Tetrahydrofuran solution and Et3B's
Tetrahydrofuran solution；Propargyl bromide is added after being stirred to react 1h；Hydrochloric acid neutralization reaction after completion of the reaction, organic extractant phase, which is evaporated, to be used in combination
The isolated compound as white solid of silica gel column chromatography 7；
The synthesis of compound 8：Compound 7 is dissolved in n,N-Dimethylformamide, and lithium iodide is added and heats, after completion of the reaction acetic acid
Ethyl ester extracts, and salt acid elution is evaporated column chromatography for separation and obtains compound as white solid 8；
The synthesis of compound 9：Compound 8 is dissolved in the mixed solvent of the tert-butyl alcohol and water, and n,N-diisopropylethylamine and corresponding is added
Nucleosides, stirring 30 minutes after be added CuI acetonitrile solution the reaction was continued overnight；Solvent evaporated after completion of the reaction, column chromatography for separation
Obtain compound 9；
The synthesis of compound 10：Compound 7 is dissolved in the mixed solvent of the tert-butyl alcohol and water, and n,N-diisopropylethylamine and corresponding is added
Nucleosides, stirring 30 minutes after be added CuI acetonitrile solution the reaction was continued overnight.Solvent evaporated after completion of the reaction, column chromatography for separation
Obtain compound 10.
Such as above-mentioned Betulonic acid derivative application in preparation of anti-tumor drugs.
The apoptosis of the derivative induced tumour cell of Betulonic acid, inhibits tumour thin at the proliferation for inhibiting tumour cell
The migration of born of the same parents.
Such as application of the above-mentioned Betulonic acid derivative in preparing antiviral drugs.
In preparation method of the present invention, the above reaction generally use thin plate chromatography method carrys out the performance level of tracking and measuring reaction,
The post-processing approach used after completion of the reaction includes concentration, extraction, column chromatography for separation etc., final product by nuclear magnetic resoance spectrum come
Verification.
Betulic acid derivative provided by the invention contains there are one Betulonic acid part, and attachment (linker) 1,
2,3- triazoles covalent bond at the C-2 of betulic acid part, attachment and the fluoro- arabinoside nucleoside part of covalent bond 2 '-.This
The compound that invention provides is chemically to be designed to deal with the water-soluble low problem of betulic acid class compound, by steady
Fixed 1,2,3- triazole attachments link together Betulonic acid and nucleoside compound.
Nucleoside compound usually has water solubility well, therefore can effectively improve compound provided by the invention and exist
Solubility in water, while the HIV-resistant activity position of betulic acid is C-3 and C-28, mechanism of action be prevent it is viral and
Cell fusion and prevention virus maturation discharge, and the mechanism of nucleoside compound AntiHIV1 RT activity is anti-reverse transcription enzyme, retains betulic acid
With the active site of nucleosides, 1,2, the 3- triazoles with antivirus action is selected to connect betulic acid and core as linker
Glycosides, can ensure the antiviral and antitumor activity of compound provided by the invention, while it is antiviral anti-to obtain new multiple target point
Tumour medicine.In addition, the toxicity of compound provided by the invention is relatively low.
Compared with the existing technology, the beneficial effects of the present invention are：By the transformation to Betulonic acid, make white birch fat ketone
Acid and active nucleosides link together, and compensate for that current betulic acid class compound water soluble is poor, bioavailability is low and core
The problems such as glycosides compound toxic side effect is big；And the simple synthetic method is feasible, yield is higher, be applied to prepare it is antitumor
Or AntiHIV1 RT activity or resisting HBV virus drug, there is preferable application value.
Specific implementation mode
Process, condition, reagent, the experimental method etc. for implementing the present invention are this in addition to the following content specially referred to
Content is not particularly limited in the common knowledge in field, the present invention.In following embodiments, compound structure is surveyed by Nuclear Magnetic Resonance
Fixed, reagent is mainly provided by Mike woods chemical reagents corporation, purifying products mainly by column chromatography, silica gel (200-300 mesh) by
Haiyang Chemical Plant, Qingdao produces.
The synthesis of 1 compound iv of embodiment
Synthesis path is as follows：
Wherein
The synthesis of compound 2：In 1000mL there-necked flasks, betulin (20.0g, 45.2mmol) and acetone (400mL) is added, so
Freshly prepd Jones reagent (100mL) is added dropwise under ice bath afterwards, the reaction was continued under ice bath, and recession in 30 minutes goes ice bath, room temperature to stir
8h is mixed, methanol (250mL) is added and water (250mL) terminates reaction, solvent evaporated is added water, is extracted with ethyl acetate, is associated with
Machine phase, dry concentration, pillar layer separation obtain white solid 2 (12.2g, 26.8mmol, 59.3%).1H NMR(DMSO-d6,
400MHz)δ：12.08 (s, 1H), 4.70 (s, 1H), 4.57 (s, 1H), 2.90~2.99 (m, 1H), 2.46~2.30 (m, 2H),
2.25 (dt, J=12.7,3.5Hz, 1H), 2.15~2.08 (m, 1H), 1.87~1.73 (m, 3H), 1.65 (s, 3H), 1.62
(s, 1H), 1.54 (t, J=11.3Hz, 1H), 1.48~1.00 (m, 15H), 0.98 (s, 3H), 0.95 (s, 3H), 0.93 (s,
3H),0.90(s,3H),0.85(s,3H)。
The synthesis of compound 6：In 100mL round-bottomed flasks, compound 2 (4.54g, 10.0mmol) is dissolved in CH2Cl2In,
0 DEG C is added dropwise oxalyl chloride (12.7g, 100mmol).Solvent evaporated after completion of the reaction, residue are added methanol and are heated to reflux, TLC prisons
Solvent evaporated after completion of the reaction is surveyed, ethyl acetate extraction, washing, organic phase Na is added2SO4Dry, pillar layer separation obtains white
Color solid chemical compound 6 (3.36g, 7.17mmol, 71.7%).1H NMR(CDCl3,400MHz)δ：4.74(s,1H),4.61(s,
1H), 3.68 (s, 3H), 3.05~2.94 (m, 1H), 2.56~2.32 (m, 2H), 2.31~2.17 (m, 2H), 1.96~1.83
(m, 3H), 1.77~1.66 (m, 1H), 1.69 (s, 3H), 1.65~1.52 (m, 6H), 1.51~1.11 (m, 13H), 1.07 (s,
3H),1.02(s,3H),0.97(s,3H),0.95(s,3H),0.92(s,3H)。13C NMR(CDCl3,100MHz)δ：218.2,
176.6,150.5,109.6,56.5,55.0,51.3,49.9,49.4,47.3,46.9,42.4,40.6,39.6,38.3,
36.9,36.9,34.2,33.6,32.1,30.6,29.6,26.6,25.5,21.4,21.0,19.6,19.4,15.9,15.7,
14.6。
The synthesis of compound 7：In 500mL round-bottomed flasks, compound 6 (2.54g, 5.42mmol) and 135mL tetra- is added
KN (the SiMe that 1mol/L is added are stirred at room temperature in hydrogen furans3)2Tetrahydrofuran solution (40mL), stir 1h after 1mol/L is added
NEt3The tetrahydrofuran solution (40mL) of B continues to stir 1.5h, propargyl bromide (4mL) is added.After completion of the reaction, 3mol/L is added
HCl (3.0mL) reaction is quenched, be extracted with ethyl acetate three times, merge organic phase, by organic phase saturated sodium bicarbonate solution
It washes twice, Na2SO4Dry, pillar layer separation obtains compound as white solid 7 (2.32g, 4.58mmol, 84.5%).1H NMR
(CDCl3,400MHz)δ：4.72 (s, 1H), 4.58 (s, 1H), 3.67 (s, 3H), 3.05~2.94 (m, 1H), 2.91~2.77
(m, 1H), 2.60 (ddd, J=17.1,4.4,2.7Hz, 1H), 2.33 (dd, J=12.9,5.6Hz, 1H), 2.29~2.10 (m,
3H), 1.94 (t, J=2.7Hz, 1H), 1.91~1.83 (m, 1H), 1.79~1.70 (m, 1H), 1.67 (s, 3H), 1.63~
1.14 (m, 14H), 1.17~1.01 (m, 3H), 1.12 (s, 3H), 1.06 (s, 3H), 1.04 (s, 3H), 0.98 (s, 3H), 0.94
(s,3H)。13C NMR(CDCl3,100MHz)δ：215.8,176.6,150.4,109.7,83.0,69.4,57.3,56.5,
51.3,50.1,49.4,48.3,47.0,46.6,42.5,41.2,40.8,38.2,37.4,36.9,34.1,32.1,30.5,
29.6,25.4,25.0,21.6,21.2,19.5,19.3,16.1,14.6。
The synthesis of compound iv：In 50mL round-bottomed flasks, compound 7 (112mg, 0.22mmol), 2 '-deoxidations-are added
2 '-fluoro- 4 '-nitrine cytidines (69mg, 0.24mmol), the tert-butyl alcohol (5mL), water (5.0mL) and DIPEA (50 μ L).It vacuumizes, nitrogen
Gas shielded is heated to 45 DEG C.After reaction 15 minutes, CuI (4.0mg) and acetonitrile (1.5mL) are added.48h is stirred at 45 DEG C.It steams
Methanol is added after dry solvent, filters, is evaporated methanol, pillar layer separation obtain faint yellow solid compound iv (144mg,
0.18mmol, 82.2%).1H NMR(MeOH-d4,400MHz)δ：7.99 (d, J=7.6Hz, 1H), 7.88 (s, 1H), 6.80
(dd, J=11.9,5.0Hz, 1H), 6.01 (d, J=7.2Hz, 1H), 5.37 (dt, J=54.0,4.7Hz, 1H), 4.79 (dd, J
=20.9,4.7Hz, 1H), 4.70 (d, J=2.0Hz, 1H), 4.59 (s, 1H), 4.40~4.18 (m, 2H), 3.65 (s, 3H),
3.26~3.09 (m, 2H), 3.06~2.92 (m, 2H), 2.62 (dd, J=14.3,6.8Hz, 1H), 2.30~2.18 (m, 2H),
2.04 (dd, J=13.0,5.3Hz, 1H), 1.92~1.81 (m, 2H), 1.76~1.00 (m, 14H), 1.68 (s, 3H), 1.11
(s, 3H), 1.06 (s, 3H), 1.04 (s, 3H), 0.98 (s, 3H), 0.98 (s, 3H), 0.94~0.82 (m, 2H).13C NMR
(MeOH-d4,100MHz)δ：218.6,178.2,166.7,151.8,144.0,124.0,110.4,98.9,96.1,76.4,
63.2,58.9,57.9,56.0,51.9,51.5,50.7,43.7,43.6,42.1,39.7,38.7,37.9,35.4,33.2,
31.7,30.9,27.0,26.8,25.7,22.3,22.1,20.4,19.6,18.8,17.4,16.8,16.6,15.2,13.3。
The synthesis of 2 compound ii of embodiment
Synthesis path is as follows：
The synthesis of compound 2：In 1000mL there-necked flasks, betulin (20.0g, 45.2mmol) and acetone (400mL) is added, so
Freshly prepd Jones reagent (100mL) is added dropwise under ice bath afterwards, the reaction was continued under ice bath, and recession in 30 minutes goes ice bath, room temperature to stir
8h is mixed, methanol (250mL) is added and water (250mL) terminates reaction, solvent evaporated is added water, is extracted with ethyl acetate, is associated with
Machine phase, dry concentration, pillar layer separation obtain white solid 2 (12.2g, 26.8mmol, 59.3%).1H NMR(DMSO-d6,
400MHz)δ：12.08 (s, 1H), 4.70 (s, 1H), 4.57 (s, 1H), 2.90~2.99 (m, 1H), 2.46~2.30 (m, 2H),
2.25 (dt, J=12.7,3.5Hz, 1H), 2.15~2.08 (m, 1H), 1.87~1.73 (m, 3H), 1.65 (s, 3H), 1.62
(s, 1H), 1.54 (t, J=11.3Hz, 1H), 1.48~1.00 (m, 15H), 0.98 (s, 3H), 0.95 (s, 3H), 0.93 (s,
3H),0.90(s,3H),0.85(s,3H)。
The synthesis of compound 3：In 100mL round-bottomed flasks, compound 2 (454mg, 1.0mmol) is dissolved in CH2Cl2
In (5mL), 0 DEG C is added EDC (306mg, 1.6mmol) and DMAP (73mg, 0.6mmol), after being stirred to react 30min, adds
L-Leu methyl ester hydrochloride (543mg, 3mmol) and Et3N (303mg, 3mmol), is stirred overnight at room temperature, and TLC monitorings have been reacted
It is washed after finishing, organic phase Na2SO4It is dry, pillar layer separation obtain syrupy shape compound 3 (343mg, 0.59mmol,
58.9%).1H NMR(CDCl3,400MHz)δ：5.87 (1H, d, J=8.2Hz), 4.72 (1H, s), 4.64 (1H, dt, J=
), 8.2,5.3Hz 4.58 (1H, s), 3.73 (3H, s), 3.11 (1H, m), 2.45 (1H, dt, J=12.2,3.4Hz), 1.68
(3H, s), 0.96 (6H, d, J=7.2Hz), 0.95 (3H, s), 0.92 (3H, s), 0.84 (6H, s), 0.83 (3H, s).
The synthesis of compound 4：In 100mL round-bottomed flasks, compound 3 (470mg, 0.81mmol) and 20mL tetra- is added
KN (the SiMe that 1mol/L is added are stirred at room temperature in hydrogen furans3)2Tetrahydrofuran solution (6mL), stir 1h after 1mol/L is added
Et3The tetrahydrofuran solution (6mL) of B continues to stir 1.5h, propargyl bromide (0.6mL) is added.After completion of the reaction, 1mol/L is added
HCl (2.0mL) reaction is quenched, be extracted with ethyl acetate three times, merge organic phase, by organic phase saturated sodium bicarbonate solution
It washes twice, Na2SO4Dry, pillar layer separation obtains compound as white solid 4 (423mg, 0.68mmol, 84.3%).1H NMR
(CDCl3,400MHz)δ：5.88 (1H, d, J=8.2Hz), 4.73 (1H, s), 4.56-4.63 (1H, m), 4.59 (1H, s),
3.72 (3H, s), 3.10 (1H, m), 2.60 (ddd, J=17.1,4.4,2.7Hz, 1H), 2.42 (1H, dt, J=12.2,
3.0Hz), 1.68 (3H, s), 0.96 (6H, d, J=7.2Hz), 0.95 (3H, s), 0.91 (3H, s), 0.82 (6H, s), 0.79
(3H,s)。
The synthesis of compound 5：In 50mL round-bottomed flasks, compound 4 (136mg, 0.22mmol), 2 '-deoxidations-are added
2 '-fluoro- 4 '-nitrine cytidines (69mg, 0.24mmol), the tert-butyl alcohol (5mL), water (5.0mL) and DIPEA (50 μ L).It vacuumizes, nitrogen
Gas shielded is heated to 45 DEG C.After reaction 15 minutes, CuI (4.0mg) and acetonitrile (1.5mL) are added.48h is stirred at 45 DEG C.It steams
Methanol is added after dry solvent, filters, is evaporated methanol, pillar layer separation obtain compound as white solid 5 (164mg, 0.18mmol,
82.5%).1H NMR(MeOH-d4,400MHz)δ：7.99 (d, J=7.6Hz, 1H), 7.88 (s, 1H), 6.80 (dd, J=
11.9,5.0Hz, 1H), 6.01 (d, J=7.2Hz, 1H), 5.37 (dt, J=54.0,4.7Hz, 1H), 4.79 (dd, J=20.9,
4.7Hz, 1H), 4.70 (d, J=2.0Hz, 1H), 4.54-4.65 (1H, m), 4.59 (1H, s), 4.40~4.18 (2H, m),
3.65 (3H, s), 3.04~2.95 (m, 1H), 2.62 (dd, J=14.3,6.8Hz, 1H), 2.30~2.18 (m, 2H), 2.04
(dd, J=13.0,5.3Hz, 1H), 1.92~1.81 (m, 2H), 1.68 (s, 3H), 1.11 (s, 3H), 1.07 (6H, d, J=
6.8Hz),1.06(s,3H),1.04(s,3H),0.98(s,3H),0.97(s,3H)。
The synthesis of compound ii：Compound 5 (90mg, 0.10mmol) is dissolved in methanol (10mL) and THF (5mL), ice bath
2mol/L KOH (2mL) are added in lower stirring, continue to keep 0 DEG C of stirring 3h.2mol/L HCl are added after completion of the reaction and use second
Acetoacetic ester extracts, and column chromatography for separation obtains compound ii (85mg, 0.095mmol, 96.2%).1H NMR(MeOH-d4,
400MHz)δ：8.02 (d, J=7.6Hz, 1H), 7.88 (s, 1H), 6.81 (dd, J=11.9,5.0Hz, 1H), 6.00 (d, J=
7.2Hz, 1H), 5.38 (dt, J=54.0,4.7Hz, 1H), 4.79 (dd, J=20.9,4.7Hz, 1H), 4.70 (d, J=
2.0Hz, 1H), 4.52-4.65 (1H, m), 4.59 (1H, s), 4.41~4.18 (2H, m), 3.06~2.97 (m, 1H), 2.63
(dd, J=13.6,6.4Hz, 1H), 2.02 (dd, J=12.6,5.0Hz, 1H), 1.68 (s, 3H), 1.11 (s, 3H), 1.07
(6H, d, J=6.8Hz), 1.06 (s, 3H), 1.04 (s, 3H), 0.95 (s, 3H), 0.89 (s, 3H).
Anticancer experiment in vitro
Ii, iv compound of this experiment various concentration are respectively acting on A549 (lung cancer), SGC-7901 (gastric cancer), MCF-7 (breasts
Gland cancer) and different types of cancer cell 72h such as LUC-7721 (liver cancer) cell, inhibitory rate of cell growth is detected by mtt assay, is come
Inhibition level of the detection compound to different tumour cells.
Ii, iv are dissolved in the DMSO of certain volume, 4 DEG C of preservations of mother liquor of a concentration of 80mmol/L is made into, uses
When take mother liquor to be diluted to the solution of certain multiple.
Concrete operation step is as follows：
(1) it takes A549, SGC-7901, MCF-7 and LUC-7721 cell in exponential phase, centrifugation to be resuspended, adjusts cell
Suspension density is inoculated in 8 × 104cell/ml in 96 well culture plates, and 100 μ l cell suspensions are added per hole, then place cell
Routine culture in incubator.
(2) after being incubated for 24 hours, original culture medium in hole is abandoned in each adherent homoepitaxial of hole cell monolayer of microscopically observation, suction,
The 100 μ l of ii, iv solution of various concentration are added in experimental group, and it is 25,50,100,200,400 μ to make final compound concentration respectively
Mol/L, each concentration are all provided with 4 multiple holes；Blank group (culture medium is only added and is not added with cell suspension), negative control group are set simultaneously
(cell suspension is only added).
(3) after placing incubator culture 72h, 20 μ l MTT solution are added per hole, continue to cultivate 4h in the incubator.Then
Culture medium carefully is discarded, 150 μ l DMSO are added per hole keeps crystal fully molten as 37 DEG C of isothermal vibration 10min on shaking table
Solution.Each hole absorbance OD values are detected under enzyme-linked immunosorbent assay instrument 490nm wavelength.
(4) inhibiting effect of the sample to cell is calculated, formula is as follows：
Inhibiting rate (%)=(cell control well OD values-dosing holes OD values)/(cell control well OD values-blank well OD values) ×
100%
According to the inhibiting rate calculated, the cytostatic half-inhibition concentration IC of each sample is found out50。
By table it can be seen that：There are not lung cancer, gastric cancer, breast cancer and liver cancer cells in ii, iv sample of doses
With the inhibiting effect of degree；Identical in action time, with the increase of sample dose, inhibiting rate is gradually increasing, right
The inhibiting effect of cell shows as apparent dose-dependent effect；Ii presses down stomach cancer cell, liver cancer cells and breast cancer cell
It makes of notable compared with lung carcinoma cell, wherein, IC preferable to gastric cancer inhibition50It is worth relatively low (explanation to ii of addition).Iv pairs
Lung cancer, the inhibiting effect of stomach cancer cell are more notable compared to breast cancer, liver cancer cells, wherein, IC preferable to gastric cancer inhibition50
It is worth relatively low.
It specifically see the table below shown：
Table 1：Inhibiting effect of the iv to each cell
Table 2：Inhibiting effect of the ii to each cell
What has been described above is only a preferred embodiment of the present invention, it is noted that for those skilled in the art,
Under the premise of not departing from general idea of the present invention, several changes and improvements can also be made, these should also be considered as the present invention's
Protection domain.
Claims (6)
1. a kind of Betulonic acid derivative or its pharmaceutically acceptable salt, hydrate or prodrug, it is characterised in that：It is tied
Shown in structure formula such as formula (I)：
Wherein：X=NH or O, Y=OH or NH2, R1It is H or R1It is C1-C20Substitution or unsubstituted group.
2. Betulonic acid derivative according to claim 1, it is characterised in that：Structural formula white birch as shown in formula (I)
Liponic acid derivative is specially structural formula such as formula i, ii, iii, iv, v, vi compounds represented：
3. the synthetic method of Betulonic acid derivative as described in claim 1, it is characterised in that：Synthesis path is as follows：
Wherein：Y=OH or NH2, R1It is C1-C20Substitution or unsubstituted group；
Specific synthesis step is as follows：
The synthesis of compound 2：Compound 1 is dissolved in acetone or tetrahydrofuran, 0 DEG C of addition Jones reagent, after completion of the reaction
Methanol and water quenching is added to go out reaction, solvent evaporated extracts and uses column chromatography to obtain compound as white solid 2；
The synthesis of compound 3：Compound 2 is dissolved in dichloromethane, 0 DEG C is added 1- (3- dimethylamino-propyls) -3- ethyls carbon two
Inferior amine salt hydrochlorate (EDC), 4-dimethylaminopyridine (DMAP) stir 30min, add corresponding amine, are stirred at room temperature and reacted
Night, extraction are evaporated column chromatography for separation and obtain compound 3；
The synthesis of compound 4：Compound 3 is dissolved in tetrahydrofuran, and KN (SiMe are added3)2Tetrahydrofuran solution and Et3B's
Tetrahydrofuran solution；Propargyl bromide is added after being stirred to react 1h.Hydrochloric acid neutralization reaction after completion of the reaction, organic extractant phase are evaporated rear pillar
Chromatographic isolation obtains compound 4；
The synthesis of compound 5：Compound 4 is dissolved in the mixed solvent of the tert-butyl alcohol and water, and n,N-diisopropylethylamine and corresponding is added
Nucleosides, stirring 30 minutes after be added CuI acetonitrile solution the reaction was continued overnight.Solvent evaporated after completion of the reaction, pillar layer separation
Obtain compound 5.
The synthesis of compound 6：Compound 2 is dissolved in dichloromethane, and 0 DEG C of dropwise addition oxalyl chloride, solvent evaporated, is re-dissolved in after completion of the reaction
CH2Cl2, corresponding alcohol stirring is added, is evaporated to obtain compound 6；
The synthesis of compound 7：Compound 6 is dissolved in tetrahydrofuran, and KN (SiMe are added3)2Tetrahydrofuran solution and Et3B's
Tetrahydrofuran solution；Propargyl bromide is added after being stirred to react 1h；Hydrochloric acid neutralization reaction after completion of the reaction, organic extractant phase, which is evaporated, to be used in combination
The isolated compound as white solid of silica gel column chromatography 7；
The synthesis of compound 8：Compound 7 is dissolved in n,N-Dimethylformamide, and lithium iodide is added and heats, after completion of the reaction acetic acid
Ethyl ester extracts, and salt acid elution is evaporated column chromatography for separation and obtains compound as white solid 8；
The synthesis of compound 9：Compound 8 is dissolved in the mixed solvent of the tert-butyl alcohol and water, and n,N-diisopropylethylamine and corresponding is added
Nucleosides, stirring 30 minutes after be added CuI acetonitrile solution the reaction was continued overnight；Solvent evaporated after completion of the reaction, column chromatography for separation
Obtain compound 9；
The synthesis of compound 10：Compound 7 is dissolved in the mixed solvent of the tert-butyl alcohol and water, and n,N-diisopropylethylamine and corresponding is added
Nucleosides, stirring 30 minutes after be added CuI acetonitrile solution the reaction was continued overnight.Solvent evaporated after completion of the reaction, column chromatography for separation
Obtain compound 10.
4. Betulonic acid derivative application in preparation of anti-tumor drugs as described in any one of claims 1-3.
5. application as claimed in claim 4, it is characterised in that：The apoptosis of the derivative induced tumour cell of betulic acid,
Inhibit the proliferation of tumour cell, inhibit the migration of tumour cell.
6. application of the Betulonic acid derivative as described in any one of claims 1-3 in preparing antiviral drugs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810483853 | 2018-05-19 | ||
| CN2018104838533 | 2018-05-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108727460A true CN108727460A (en) | 2018-11-02 |
| CN108727460B CN108727460B (en) | 2019-06-07 |
Family
ID=63925527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810700317.4A Active CN108727460B (en) | 2018-05-19 | 2018-06-29 | Betulonic acid derivative and its synthetic method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108727460B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112979743A (en) * | 2019-12-02 | 2021-06-18 | 河南省医药科学研究院 | Betulinic acid derivative and application thereof |
| CN113912663A (en) * | 2020-07-07 | 2022-01-11 | 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
| CN114057823A (en) * | 2020-08-06 | 2022-02-18 | 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
| CN114344313A (en) * | 2022-01-28 | 2022-04-15 | 河南省科学院高新技术研究中心 | Betulinic acid derivatives for preventing or treating degenerative diseases of nervous system |
| CN115894600A (en) * | 2021-09-30 | 2023-04-04 | 河南省科学院高新技术研究中心 | Betulol derivative, and preparation method, pharmaceutical composition and application thereof |
| CN117327140A (en) * | 2023-11-24 | 2024-01-02 | 潍坊赛宝工业技术研究院有限公司 | Betulinic acid derivative with bacteria inhibiting function |
| CN113912663B (en) * | 2020-07-07 | 2024-05-24 | 威海赛宝工业信息技术研究院有限公司 | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1861627A (en) * | 2006-05-12 | 2006-11-15 | 中国药科大学 | 23-Hydroxyl betulinic acid kind derivant and preparing process, preparation and use thereof |
| CN102108092A (en) * | 2011-01-29 | 2011-06-29 | 暨南大学 | 23-hydroxy betulinic acid derivative as well as preparation method and application thereof |
| CN104337819A (en) * | 2013-07-26 | 2015-02-11 | 华东师范大学 | Application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation |
| CN104744549A (en) * | 2015-02-16 | 2015-07-01 | 华东师范大学 | Betulinic acid derivative as well as preparation method and application thereof in preparing antineoplastic drugs |
-
2018
- 2018-06-29 CN CN201810700317.4A patent/CN108727460B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1861627A (en) * | 2006-05-12 | 2006-11-15 | 中国药科大学 | 23-Hydroxyl betulinic acid kind derivant and preparing process, preparation and use thereof |
| CN102108092A (en) * | 2011-01-29 | 2011-06-29 | 暨南大学 | 23-hydroxy betulinic acid derivative as well as preparation method and application thereof |
| CN104337819A (en) * | 2013-07-26 | 2015-02-11 | 华东师范大学 | Application of betulinic acid derivatives in preparation of drugs inhibiting T cell differentiation |
| CN104744549A (en) * | 2015-02-16 | 2015-07-01 | 华东师范大学 | Betulinic acid derivative as well as preparation method and application thereof in preparing antineoplastic drugs |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112979743A (en) * | 2019-12-02 | 2021-06-18 | 河南省医药科学研究院 | Betulinic acid derivative and application thereof |
| CN112979743B (en) * | 2019-12-02 | 2022-05-10 | 河南省医药科学研究院 | Betulinic acid derivative and application thereof |
| CN113912663A (en) * | 2020-07-07 | 2022-01-11 | 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
| CN113912663B (en) * | 2020-07-07 | 2024-05-24 | 威海赛宝工业信息技术研究院有限公司 | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
| CN114057823A (en) * | 2020-08-06 | 2022-02-18 | 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
| CN114057823B (en) * | 2020-08-06 | 2024-01-30 | 威海赛宝工业信息技术研究院有限公司 | Betulinic acid derivative, preparation method, pharmaceutical composition and application thereof |
| CN115894600A (en) * | 2021-09-30 | 2023-04-04 | 河南省科学院高新技术研究中心 | Betulol derivative, and preparation method, pharmaceutical composition and application thereof |
| CN114344313A (en) * | 2022-01-28 | 2022-04-15 | 河南省科学院高新技术研究中心 | Betulinic acid derivatives for preventing or treating degenerative diseases of nervous system |
| CN117327140A (en) * | 2023-11-24 | 2024-01-02 | 潍坊赛宝工业技术研究院有限公司 | Betulinic acid derivative with bacteria inhibiting function |
| CN117327140B (en) * | 2023-11-24 | 2024-03-12 | 潍坊赛宝工业技术研究院有限公司 | Betulinic acid derivative with bacteria inhibiting function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108727460B (en) | 2019-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108503681B (en) | Betulic acid derivative and its synthetic method and application | |
| CN108727460B (en) | Betulonic acid derivative and its synthetic method and application | |
| CN108558985B (en) | Betulic acid derivative and its synthetic method and application | |
| CN110483608B (en) | Arenobufagin derivative, preparation method thereof, composition containing arenobufagin derivative and application of arenobufagin derivative | |
| CN103627772B (en) | The preparation method of a kind of triptolide alcohol derivative and product thereof and application | |
| CN103288913B (en) | A kind of noval chemical compound, its pharmaceutical composition, Its Preparation Method And Use | |
| EP2862869B1 (en) | Acylated derivatives of polyphyllin i, preparation method therefor and application thereof | |
| CN110922415B (en) | Synthesis and application of novel anti-tumor active compound | |
| CN111471080A (en) | ocotillol type ginsengenin A-ring amino thiazole ring derivative and preparation method thereof | |
| CN108929353B (en) | A kind of rhamnose or the berberine salt derivative and its preparation method and application of ribose modification | |
| EP2786989B1 (en) | 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof | |
| CN109734768B (en) | Deacetylated cedilanid glucose-based modified compound liposome and application thereof | |
| CN102516066B (en) | Ostopanic acid analog and Preparation method and use | |
| CN106146497A (en) | Matrine oxime ester derivative and preparation method and application | |
| CN106366088A (en) | Parthenolide derivative, and medicinal composition, preparation method and use thereof | |
| CN110804084B (en) | Quaternary phosphonium salt diosgenin derivative and synthesis method and application thereof | |
| CN102838652B (en) | A kind of oleanolic acid derivate with anticarcinogenesis and its production and use | |
| CN104672251B (en) | A kind of semisynthesis of 17- hydroxyls-jolkinolide B | |
| CN108864132A (en) | A kind of Oridonin derivative and its preparation method and application | |
| CN109369634B (en) | Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity | |
| CN113773356B (en) | Picroside II derivative and preparation method and application thereof | |
| CN104334571B (en) | The acylated derivatives of Rhizoma Paridis saponin I, and its preparation method and application | |
| CN103275157B (en) | The rupestonic acid amide derivatives containing heterocycle and sugar and preparation method and purposes | |
| CN113402578B (en) | Diosgenin derivative and preparation method and medical application thereof | |
| CN106008545B (en) | The compound salt derivative of Norcantharidin and its antitumor application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |